



Dedicated To Life

May 19, 2026

BSE Limited
Department of Corporate Relations
Pheroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra - Kurla Complex, Mumbai - 400 051

Scrip Code: 532321

Symbol: ZYDUSLIFE

Sub: Outcome of the meeting of the Board of Directors ("Board")

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Dear Sir / Madam,

In continuation of our letter dated May 13, 2026, and in terms of Regulation 30 of Listing Regulations, we wish to inform you that the Board of the Zydus Lifesciences Limited ("**Company**"), at its meeting held today (i.e., May 19, 2026), has *inter-alia*, considered and approved:

- (i) the proposal to buyback up to 95,65,217 (Ninety Five Lakhs Sixty Five Thousand Two Hundred Seventeen) fully paid-up equity shares of the Company, each having a face value of INR 1/- (Indian Rupee One only) ("**Equity Shares**"), representing up to 0.95 % of the total number of equity shares in the paid-up equity share capital of the Company, at a price of INR 1,150/- (Indian Rupees One Thousand One Hundred Fifty only) per Equity Share ("**Buyback Price**") payable in cash for an aggregate amount not exceeding INR 1100,00,00,000/- (One Thousand One Hundred Crores only) ("**Buyback Size**") being 5.16% and 3.84% of the aggregate of the fully paid-up equity share capital and free reserves as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2026, respectively. The Buyback Size does not include transaction costs viz. brokerage costs, fees, turnover charges, applicable taxes such as buyback tax, securities transaction tax, goods and services tax, stamp duty, etc., and expenses incurred or to be incurred for the buyback like filing fees payable to the Securities and Exchange Board of India ("**SEBI**"), advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.

The buyback is proposed to be made from all of the equity shareholders / beneficial owners of the Company including the promoters and members of the promoter group of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011), who hold Equity Shares as of the record date (as mentioned below), on a proportionate basis through the "tender offer" route, in accordance with the provisions contained in the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("**Buyback Regulations**") and the Companies Act, 2013, as amended and rules made thereunder;

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



- (ii) the formation of a buyback committee (“**Buyback Committee**”) and delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback; and
- (iii) May 29, 2026 (“**Record Date**”) as the record date for the purpose of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback, in accordance with Regulation 42 of the Listing Regulations and Regulation 9(i) of the Buyback Regulations.

In terms of Regulation 5(via) of the Buyback Regulations, the Board/ Buyback Committee may, till 1 (one) working day prior to the Record Date, increase the Buyback price and decrease the number of Equity Shares proposed to be bought back, such that there is no change in the Buyback Size.

The pre-buyback shareholding pattern as on May 15, 2026, is enclosed as **Annexure A**. Please note that the details regarding the post-buyback shareholding pattern have not been provided since the actual number of Equity Shares that are bought back and category of shareholders from whom the Equity Shares will be bought back can be determined after the Record Date.

The public announcement and the letter of offer setting out the process, timelines, and other requisite details will be released in due course in accordance with the Buyback Regulations.

The relevant details as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/ 2026 dated July 11, 2023, and updated on January 30, 2026, are given as **Annexure B**.

We would like to inform you that the said meeting commenced at 12:00 noon and concluded at 2:00 p.m.

We request you to kindly take the above on record.

Thanking you,

For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary & Compliance Officer
Membership No. FCS7063

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Annexure - A

Pre-buyback shareholding pattern of the Company as on May 15, 2026 is set out below:

S. No.	Shareholder Category	Number of shareholders	No. of equity shares held	% of shareholding
1.	Promoter and promoter group	12	75,46,25,314	74.9950
2.	Mutual funds	161	4,92,83,636	4.8978
3.	Alternative investment funds	12	3,82,953	0.0381
4.	Foreign portfolio investor	677	6,90,13,371	6.8586
5.	Financial institutions / banks	7	5,39,581	0.0536
6.	Insurance companies	30	6,15,76,172	6.1195
7.	Central/ State Governments	3	16,504	0.0016
8.	Individuals (upto INR 2 lacs)	4,14,170	4,88,14,256	4.8512
9.	Individuals (above INR 2 lacs)	6	72,02,910	0.7158
10.	NBFCs registered with RBI	4	2,246	0.0002
11.	Investor Education Protection Fund	1	17,19,113	0.1708
12.	Trusts	18	1,97,918	0.0197
13.	HUF	4,909	15,05,713	0.1496
14.	NRIs (repat and non-repat)	10,783	33,82,862	0.3362
15.	Bodies corporate/ clearing members	1,028	59,71,790	0.5935
16.	LLP, foreign nationals	119	3,11,814	0.0310
17.	Unclaimed or Suspense or Escrow Account	1	1,45,320	0.0144
18.	Others	10	15,42,517	0.1533
Total		4,31,951	100,62,33,990	100.0000

Note: The post buyback shareholding pattern of the Company shall be ascertained subsequently.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Annexure - B

Details as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/ 2026 dated July 11, 2023 and updated on January 30, 2026

S. No.	Particulars	Description
1.	Number of securities proposed for buyback	95,65,217
2.	Number of securities proposed for buyback as a percentage of existing paid-up capital	0.95%
3.	Buyback price	Rs. 1,150/- per share
4.	Actual securities in number and percentage of existing paid-up capital bought back	Not applicable
5.	Pre and post buyback shareholding pattern	Pre buyback shareholding pattern of the Company is provided in Annexure A and the post buyback shareholding shall be ascertained subsequently.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

